文献速递胃肠动力与功能性疾病

肠易激综合征:基于病理生理学和生物标志物的治疗

Irritable bowel syndrome: treatment based on pathophysiology and biomarkers.
PubMed 文献 · Gut · 2022-10-28

该综述通过PubMED文献回顾,评估病理生理机制及针对这些机制的个体化治疗作为肠易激综合征(IBS)治疗替代方案的可能性。文章指出,多种无创临床检测可评估IBS症状产生机制,基本分子机制日益明确,为针对食物成分、受体及微生物组的药物干预提供机会。尽管各机制干预证据水平不一,当前技术水平使基于病理生理学和临床可识别生物标志物的个体化治疗成为可能。

要点

  • 无创临床检测可评估IBS症状产生机制,包括直肠排空障碍、转运异常、内脏高敏感或高警觉、胆汁酸性腹泻、糖不耐受、屏障功能障碍、微生物组、免疫激活及后者释放的化学物质。
  • 基本分子机制日益明确,为针对食物成分、受体及微生物组的药物干预提供机会。
  • 当前技术水平使IBS治疗从基于症状转向基于病理生理学和临床可识别生物标志物的个体化治疗成为可能。

核心结论

  • 这些进展为基于可操作生物标志物或心理障碍的IBS循证个体化治疗的实施提供了良好前景。

研究设计与样本

  • 由两位作者独立进行的基于PubMED的IBS机制与治疗文献综述,观点或解读差异经讨论解决。

主要发现

  • 多种无创临床检测可评估IBS症状产生机制,包括直肠排空障碍、转运异常、内脏高敏感或高警觉、胆汁酸性腹泻、糖不耐受、屏障功能障碍、微生物组、免疫激活及后者释放的化学物质。
  • 基本分子机制日益明确,为针对食物成分、受体及可能针对微生物组的药物干预提供机会。
  • 支持每种机制干预的证据并非处于相同证明水平。
  • 当前技术水平使治疗从基于症状转向由病理生理学和临床可识别生物标志物指导的个体化治疗成为可能。

临床怎么用

  • 原文结论未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To appraise the evidence that pathophysiological mechanisms and individualised treatment directed at those mechanisms provide an alternative approach to the treatment of patients with irritable bowel syndrome (IBS). DESIGN: A PubMED-based literature review of mechanisms and treatment of IBS was conducted independently by the two authors, and any differences of perspective or interpretation of the literature were resolved following discussion. RESULTS: The availability of several noninvasive clinical tests can appraise the mechanisms responsible for symptom generation in IBS, including rectal evacuation disorders, abnormal transit, visceral hypersensitivity or hypervigilance, bile acid diarrhoea, sugar intolerances, barrier dysfunction, the microbiome, immune activation and chemicals released by the latter mechanism. The basic molecular mechanisms contributing to these pathophysiologies are increasingly recognised, offering opportunities to intervene with medications directed specifically to food components, receptors and potentially the microbiome. Although the evidence supporting interventions for each mechanism is not at the same level of proof, the current state-of-the-art provides the opportunity to advance the practice from treatment based on symptoms to individualisation of treatment guided by pathophysiology and clinically identified biomarkers. CONCLUSION: These advances augur well for the implementation of evidence-based individualised treatment for patients with IBS based on actionable biomarkers or psychological disturbances.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Camilleri M, Boeckxstaens G. Irritable bowel syndrome: treatment based on pathophysiology and biomarkers. Gut. 2022. PMID: 36307180. doi:10.1136/gutjnl-2022-328515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。